Chemical tools to monitor bladder cancer progression

References

• Abreu, B.J., and de Brito Vieira, W.H., 2016. Metalloproteinase changes in diabetes. Advances in experimental medicine and biology, 920, 185–190.
   PubMed Web of Science ®Google Scholar
• Al Za'abi, M., et al., 2016. Analyses of acute kidney injury biomarkers by ultra-high performance liquid chromatography with mass spectrometry. Journal of separation science, 39 (1), 69–82.
   PubMed Web of Science ®Google Scholar
• Al Za'abi, M., Ali, B.H., and Ali, I., 2015. Advances in the methodologies for the analysis of acute kidney injury biomarkers. Recent patents on biomarkers, 5 (2), 81–92.
   Google Scholar
• Ali, I., Aboul-Enein, H.Y., and Ghanem, A., 2005. Enantioselective toxicity and carcinogenesis. Current pharmaceutical analysis, 1 (1), 109–125.
   Web of Science ®Google Scholar
• Ali, I., et al., 2011. Role of chromatography for monitoring of breast cancer biomarkers. Recent patents on biomarkers, 1, 89–97.
   Google Scholar
• Ali, I., et al., 2013. Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future medicinal chemistry, 5 (8), 961–978.
   PubMed Web of Science ®Google Scholar
• Arenas, J., et al., 1988. Arylsulfatase A in urine of patients with urothelial tumors. Clinical biochemistry, 21 (1), 73–77.
   PubMed Web of Science ®Google Scholar
• Bredin, H.C., Daly, J.J., and Prout, G.R., Jr 1975. Lactic dehydrogenase isoenzymes in human bladder cancer. The journal of urology, 113 (4), 487–490.
   PubMed Web of Science ®Google Scholar
• Chen, Y.T., et al., 2010. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. Journal of proteome research, 9 (11), 5803–5815.
   PubMed Web of Science ®Google Scholar
• Chen, Y.T., et al., 2012. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. Journal of proteomics, 75 (12), 3529–3545.
   PubMed Web of Science ®Google Scholar
• Citron, M., et al., 1996. Inhibition of amyloid beta-protein production in neural cells by the serine protease inhibitor AEBSF. Neuron, 17 (1), 171–179.
   PubMed Web of Science ®Google Scholar
• Dudani, J.S., Warren, A.D., and Bhatia, S.N., 2017. Harnessing protease activity to improve cancer care. Annual review of cancer biology, 10, 353–376.
   Google Scholar
• Egeblad, M., and Werb, Z., 2002. New functions for the matrix metalloproteinases in cancer progression. Nature reviews. Cancer, 2 (3), 161–174.
   PubMed Web of Science ®Google Scholar
• Ellis, W.J., et al., 1997. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The multi center study group. Urology, 50 (6), 882–887.
   PubMed Web of Science ®Google Scholar
• Ferro, M., et al., 2020. Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Urologic oncology: seminars and original investigations, 38 (5), 459–464.
   PubMed Web of Science ®Google Scholar
• Ferro, M., et al., 2021. Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. Minerva urology and nephrology, 73 (6), 796–802.
   PubMedGoogle Scholar
• Ferro, M., et al., 2019. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World journal of urology, 37 (3), 507–514.
   PubMed Web of Science ®Google Scholar
• Folgueras, A.R., et al., 2004. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. The international journal of developmental biology, 48 (5–6), 411–424.
   PubMed Web of Science ®Google Scholar
• Gault, M.H., and Geggie, P.H., 1969. Clinical significance of urinary LDH, alkaline phosphatase and other enzymes. Canadian medical association journal, 101 (4), 208–215.
   PubMed Web of Science ®Google Scholar
• Grimm, J., et al., 2005. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proceedings of the national academy of sciences of the United States of America, 102 (40), 14404–14409.
   PubMed Web of Science ®Google Scholar
• Gruba, N., Stachurski, L., and Lesner, A., 2021a. Elastolytic activity is associated with inflammation in bladder cancer. Journal of biochemistry, 170(4):547–558.
   PubMed Web of Science ®Google Scholar
• Gruba, N., Stachurski, L., and Lesner, A., 2021b. Non-proteasomal urine activity in bladder cancer. Chemistry & biodiversity, 18 (3), e2000981.
   PubMed Web of Science ®Google Scholar
• Gruba, N., et al., 2016b. Novel internally quenched substrate of the trypsin-like subunit of 20S eukaryotic proteasome. Analytical biochemistry, 508, 38–45.
   PubMed Web of Science ®Google Scholar
• Gruba, N., et al., 2016a. Bladder cancer detection using a peptide substrate of the 20S proteasome. The FEBS journal, 283 (15), 2929–2948.
   PubMed Web of Science ®Google Scholar
• Guarino, C., et al., 2014. New selective peptidyl di(chlorophenyl) phosphonate esters for visualizing and blocking neutrophil proteinase 3 in human diseases. The journal of biological chemistry, 289 (46), 31777–31791.
   PubMed Web of Science ®Google Scholar
• Guo, A., et al., 2014. Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: a meta-analysis. Canadian urological association journal, 8 (5-6), 347–E352.
   PubMedGoogle Scholar
• Han, J., et al., 2020. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomedicine & pharmacotherapy, 129, 110393.
   PubMed Web of Science ®Google Scholar
• Hanahan, D., and Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. Cell, 144 (5), 646–674.
   PubMed Web of Science ®Google Scholar
• Herszényi, L., et al., 2014. Impact of proteolytic enzymes in colorectal cancer development and progression. World journal of gastroenterology, 20 (37), 13246–13257.
   PubMed Web of Science ®Google Scholar
• Herszényi, L., et al., 2000. Proteases in gastrointestinal neoplastic diseases. Clinica chimica acta; international journal of clinical chemistry, 291 (2), 171–187.
   PubMed Web of Science ®Google Scholar
• Hirano, K., et al., 1987. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels. Journal of the national cancer institute, 79 (6), 1261–1268.
   PubMedGoogle Scholar
• Hussain, A., et al., 2019. Biogenesis of ZnO nanoparticles using Pandanus odorifer leaf extract: anticancer and antimicrobial activities. RSC advances, 9 (27), 15357–15369.
   PubMed Web of Science ®Google Scholar
• Itzkowitz, S.H., and Kim, Y.S., 1986. New carbohydrate tumor markers. Gastroenterology, 90 (2), 491–494.
   PubMed Web of Science ®Google Scholar
• Itzkowitz, S.H., et al., 1988. Immunohistochemical comparison of Lea, monosialosyl Lea (CA 19-9), and disialosyl Lea antigens in human colorectal and pancreatic tissues. Cancer research, 48 (13), 3834–3842.
   PubMed Web of Science ®Google Scholar
• Kim, H.S., and Ku, J.H., 2016. Systemic inflammatory response based on neutrophil-to-lymphocyte ratio as a prognostic marker in bladder cancer. Disease markers, 2016, 8345286.
   PubMed Web of Science ®Google Scholar
• Kim, J., et al., 1998. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell, 94 (3), 353–362.
   PubMed Web of Science ®Google Scholar
• Kuo, C.S., et al., 2020. Inhibition of serine protease activity protects against high fat diet-induced inflammation and insulin resistance. Scientific reports, 10 (1), 1725.
   PubMed Web of Science ®Google Scholar
• Lewandowski, K.C., et al., 2011. Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemia. Archives of medical science, 2, 294–303.
   Google Scholar
• Lin, C., et al., 2015. Infiltrating neutrophils increase bladder cancer cell invasion via modulation of androgen receptor (AR)/MMP13 signals. Oncotarget, 6 (40), 43081–43089.
   PubMedGoogle Scholar
• Liotta, L.A., and Stetler-Stevenson, W.G., 1991. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer research, 51 (18 Suppl), 5054s–5059s.
   PubMed Web of Science ®Google Scholar
• Lokeshwar, V.B., et al., 2005. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology, 66 (6 Suppl 1), 35–63.
   PubMedGoogle Scholar
• Man, Y.G., et al., 2013. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. Journal of cancer, 4 (1), 84–95.
   PubMed Web of Science ®Google Scholar
• Marchewka, Z., et al., 2018. Low molecular weight proteins and enzymes in the urine of patients with bladder cancer - a pilot study. Central European journal of urology, 71 (3), 280–286.
   PubMed Web of Science ®Google Scholar
• Martin, M.D., and Matrisian, L.M., 2007. The other side of MMPs: protective roles in tumor progression. Cancer metastasis reviews, 26 (3-4), 717–724.
   PubMed Web of Science ®Google Scholar
• Maru, A., et al., 1980. Arylsulfatase A activity of urine in patients with various genitourinary tract disorder. Clinica chimica acta., 107, 155–161.
   PubMed Web of Science ®Google Scholar
• Mason, S.D., and Joyce, J.A., 2011. Proteolytic networks in cancer. Trends in cell biology, 21 (4), 228–237.
   PubMed Web of Science ®Google Scholar
• Massicotte, C., et al., 1999. Neuropathologic effects of phenylmethylsulfonyl fluoride (PMSF)-induced promotion and protection in organophosphorus ester-induced delayed neuropathy (OPIDN) in hens. Neurotoxicology, 20, 749–759.
   PubMed Web of Science ®Google Scholar
• Masuda, N., et al., 2018. Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer. Oncotarget, 9 (6), 7101–7111.
   PubMedGoogle Scholar
• Meng, L., et al., 1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proceedings of the national academy of sciences of the United States of America, 96 (18), 10403–10408.
   PubMed Web of Science ®Google Scholar
• Mignatti, P., and Rifkin, D.B., 1993. Biology and biochemistry of proteinases in tumor invasion. Physiological reviews, 73 (1), 161–195.
   PubMed Web of Science ®Google Scholar
• Moonen, P.M., Kiemeney, L.A., and Witjes, J.A., 2005. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. European urology, 48 (6), 951–956.
   PubMed Web of Science ®Google Scholar
• Ng, K., et al., 2021. Urinary biomarkers in bladder cancer: a review of the current landscape and future directions. Urologic oncology, 39 (1), 41–51.
   PubMed Web of Science ®Google Scholar
• Paigen, B., Yarfitz, S., and Tabron, D., 1984. Urinary glucuronidase and arylsulfatases in identical twins of bladder cancer. Cancer research, 44 (8), 3624–3626.
   PubMed Web of Science ®Google Scholar
• Pall, M., et al., 2012. CA 19-9 as a serum marker in urothelial carcinoma. Urol ann, 4, 98–101.
   PubMedGoogle Scholar
• Posey, L.E., and Morgan, L.R., 1977. Urine enzyme activities in patients with transitional cell carcinoma of the bladder. Clinica chimica acta; international journal of clinical chemistry, 74 (1), 7–10.
   PubMed Web of Science ®Google Scholar
• Rmali, K.A., Puntis, M.C., and Jiang, W.G., 2007. Tumour-associated angiogenesis in human colorectal cancer. Colorectal disease: the official journal of the association of coloproctology of Great Britain and Ireland, 9 (1), 3–14.
   PubMed Web of Science ®Google Scholar
• Roy, S., Dasgupta, A., and Kar, K., 2013. Comparison of urinary and serum CA 19-9 as markers of early stage urothelial carcinoma. International Braz j urol : official journal of the Brazilian society of urology, 39 (5), 631–638.
   PubMed Web of Science ®Google Scholar
• Różański, W., et al., 2011. Diagnostic value of β-N-acetyl-D-glucosaminidase and endoglin as molecular markers in postmenopausal women with urinary bladder neoplasms. Menopause review, 3, 197–201.
   Google Scholar
• Saleem, K., et al., 2013. Synthesis, DNA binding, hemolysis assays and anticancer studies of copper(II), nickel(II) and iron(III) complexes of a pyrazoline-based ligand. Future medicinal chemistry, 5 (2), 135–146.
   PubMed Web of Science ®Google Scholar
• Sashide, K., et al., 2004. CA19-9 as a serum marker for poor prognosis in urothelial carcinoma. Urologia internationalis, 72 (2), 112–117.
   PubMed Web of Science ®Google Scholar
• Severini, G., et al., 1995. A study of serum glycosidases in cancer. Journal of cancer research and clinical oncology, 121 (1), 61–63.
   PubMed Web of Science ®Google Scholar
• Shabayek, M.I., et al., 2014. Diagnostic evaluation of urinary angiogenin (ANG) and clusterin (CLU) as biomarker for bladder cancer. Pathology oncology research: POR, 20 (4), 859–866.
   PubMed Web of Science ®Google Scholar
• Soukup, V., et al., 2015. Panel of urinary diagnostic markers for non-invasive detection of primary and recurrent urothelial urinary bladder carcinoma. Urologia internationalis, 95 (1), 56–64.
   PubMed Web of Science ®Google Scholar
• Steele, J.M., 2013. Carfilzomib: a new proteasome inhibitor for relapsed or refractory multiple myeloma. Journal of oncology pharmacy practice: official publication of the international society of oncology pharmacy practitioners, 19 (4), 348–354.
   PubMedGoogle Scholar
• Sun, J., 2010. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. Journal of signal transduction, 2010, 985132.
   PubMedGoogle Scholar
• Tizzani, A., et al., 1987. Tumor markers (CEA, TPA and CA 19-9) in urine of bladder cancer patients. The international journal of biological markers, 2 (2), 121–124.
   PubMedGoogle Scholar
• Tsioufis, C., et al., 2012. The role of matrix metalloproteinases in diabetes mellitus. Current topics in medicinal chemistry, 12 (10), 1159–1165.
   PubMed Web of Science ®Google Scholar
• Wang, W.S., et al., 2002. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepato-gastroenterology, 49, 160–164.
   PubMedGoogle Scholar
• Weissleder, R., 2006. Molecular imaging in cancer. Science (New York, N.Y.), 312 (5777), 1168–1171.
   PubMed Web of Science ®Google Scholar
• Winiarski, Ł., Oleksyszyn, J., and Sieńczyk, M., 2012. Human neutrophil elastase phosphonic inhibitors with improved potency of action. Journal of medicinal chemistry, 55 (14), 6541–6553.
   PubMed Web of Science ®Google Scholar
• Yang, Y., et al., 2009. Molecular imaging of proteases in cancer. Cancer growth metastasis, 2, 13–27.
   PubMedGoogle Scholar
• Yang, Y., Xu, J., and Zhang, Q., 2018. Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B. Oncology letters, 15 (5), 7923–7933.
   PubMed Web of Science ®Google Scholar
• Yoon, S.O., et al., 2003. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. Journal of biochemistry and molecular biology, 36 (1), 128–137.
   PubMedGoogle Scholar
• Youssef, E.M., et al., 1999. Elevation of urinary enzyme levels in rat bladder carcinogenesis. Carcinogenesis, 20 (7), 1247–1252.
   PubMed Web of Science ®Google Scholar
• Zhang, H.C., et al., 2005. Leupeptin-sensitive proteases involved in cell survival after X-ray irradiation in human RSa cells. Cell biology international, 29 (8), 662–668.
   PubMed Web of Science ®Google Scholar